Skip to main content
. 2017 Jun 6;12(6):e0179063. doi: 10.1371/journal.pone.0179063

Fig 2. Oral glucose tolerance test in SHR and SHR-CRP transgenic rats treated with placebo or with salsalate.

Fig 2

A. SHR-CRP transgenic rats treated with salsalate exhibited significantly reduced glucose concentrations (similar to both treated and untreated SHR rats) when compared to SHR-CRP rats treated with placebo. No significant effects of treatment were observed in nontransgenic SHR rats. B. Area under the curve (AUC) for glucose concentrations in SHR-CRP rats treated with salsalate was significantly reduced when compared to untreated SHR-CRP rats. * denotes significant differences (P<0.05) between SHR-CRP rats treated with salsalate versus all other groups; † denotes significant strain x treatment interactions, i.e. salsalate treatment protects against the adverse effects of human CRP.